Half of all heart failure patients have preserved ejection fraction (HFpEF). Comorbidities associated with and contributing to HFpEF include obesity, diabetes and hypertension. Still, the underlying pathophysiological mechanisms of HFpEF are unknown. A preliminary consensus proposes that the multi-morbidity triggers a state of systemic, chronic low-grade inflammation, and microvascular dysfunction, causing reduced nitric oxide bioavailability to adjacent cardiomyocytes. As a result, the cardiomyocyte remodels its contractile elements and fails to relax properly, causing diastolic dysfunction, and eventually HFpEF. HFpEF is a complex syndrome for which currently no efficient therapies exist. This is notably due to the current one-size-fits-all therapy approach that ignores individual patient differences. MicroRNAs have been studied in relation to pathophysiological mechanisms and comorbidities underlying and contributing to HFpEF. As regulators of gene expression, microRNAs may contribute to the pathophysiology of HFpEF. In addition, secreted circulating microRNAs are potential biomarkers and as such, they could help stratify the HFpEF population and open new ways for individualized therapies. In this review, we provide an overview of the ever-expanding world of non-coding RNAs and their contribution to the molecular mechanisms underlying HFpEF. We propose prospects for microRNAs in stratifying the HFpEF population. MicroRNAs add a new level of complexity to the regulatory network controlling cardiac function and hence the understanding of gene regulation becomes a fundamental piece in solving the HFpEF puzzle.
Introducing HFpEF
Heart failure (HF) is one of the major causes of death and disability worldwide characterized by impairment of ventricular filling or ejection leading to limited cardiac output to the body, with cardinal symptoms of dyspnoea, fatigue, and exercise intolerance. One-half of patients with HF have a preserved ejection fraction (HFpEF), and the prevalence of HFpEF is growing relative to HF with reduced EF (HFrEF) at an alarming rate of 1% per year. 1 Compared to HFrEF patients, HFpEF patients are generally older, more frequently female, and have increased incidence of comorbidities as hypertension, type 2 diabetes, obesity, anemia, chronic kidney disease, chronic obstructive pulmonary disease, and atrial fibrillation. 1 Importantly, although for specific HFpEF phenotypes targeted therapy seems promising, 2, 3 there is still lack of effective treatment for the general HFpEF population.
Pathophysiology of HFpEF
The pathophysiology underlying HFpEF remains a subject of intense debate. Recent investigations indicate systemic low-grade inflammation and microvascular dysfunction (MVD) secondary to co-morbidities to be keystones in the etiology of HFpEF ( Figure 1 ). Low-grade inflammation is a pathological feature of a wide range of chronic conditions including the metabolic syndrome and involves both leucocyte infiltration into tissues and the presence of a pro-inflammatory milieu with high cytokine and chemokine levels. MVD, in particular metabolic syndromeassociated capillary rarefaction, affects peripheral vascular resistance and blood pressure, as well as (cardiac) muscle perfusion and metabolism. 4 In addition, inflammation aggravates MVD, directly or indirectly via metabolic syndrome-associated oxidative stress. The cardiomyocyte 'senses' these pathological events in more than one way. Reduced cardiac perfusion hampers the supply and diffusion of nutrients to the cardiomyocyte.
nostic criteria for HFpEF are subject to broad interpretation. Moreover, signs and symptoms of HFpEF are the same as in HFrEF. In addition, HFpEF related co-morbidities are confounders in the diagnosis. The heterogeneity of HFpEF patients is certainly the biggest hurdle for the interpretation of trial studies. So far all efforts pursued on finding an effective treatment for HFpEF have failed and the current therapy is limited to diuretics and the treatment of co-morbidities. 6 New efforts should be urged to achieve effective patient phenotyping in order to improve the design of new trials where a wide range of possible treatments should be taken into account. Classical biomarkers, echocardiographic measurements, Figure 1 Pathophysiology of HfpEF. Comorbidities drive a status of systemic inflammation and microvascular disease (MVD), marked by increased plasma levels of inflammatory cytokines such as c-reactive protein (CRP), interleukin-1 (IL-1), interleukin-6 (IL-6), growth differentiation factor 15 (GDF15), tumor necrosis factor alpha (TNFa). The inflammation status has effect on multiple organs including the heart where it induces microvascular endothelial dysfunction with upregulation of VCAM and E-selectin and subsequent leucocyte infiltration. The result is the activation myocardial pro-inflammatory and profibrotic processes, cardiomyocyte stiffness, metabolic remodelling, and interstitial collagen deposition.
and clinical parameters seem insufficient to identify different HFpEF pheno-groups with unique underlying pathophysiology and to evaluate the response to personalized therapy. New biomarkers are necessary to complement the existing ones. 7 Here, we provide an update on the ever-expanding role of microRNAs in the molecular mechanisms underlying HFpEF. We propose prospects for extracellular microRNAs in stratifying the HFpEF population and in clarifying the underlying pathophysiology. Though still at its infancy, the putative therapeutic applications of microRNAs in HFpEF are discussed and ground for further research is provided. Each topic will be introduced with a clinical background before going into the molecular details of the associated microRNA implications.
Role of microRNAs in the pathophysiology of HFpEF

Introduction into the world of the noncoding microRNAs
Advancements in next generation sequencing, gene silencing, and editing technologies have fuelled the investigation of several classes of noncoding RNA, including microRNAs. A growing body of literature has investigated the role of microRNAs which are considered to play critical roles during development, health, and disease. 8 MicroRNAs are small non-coding molecules of 22 nucleotides that fine-tune gene expression via targeting mRNA for translational inhibition. 8 Below we will discuss the biological relevance of microRNAs involved in the pathophysiological processes considered to be important in HFpEF etiology, namely (1) inflammation, (2) microvascular endothelial dysfunction, (3) cardiomyocyte remodelling, and (4) fibrosis.
MicroRNAs in inflammation
Inflammatory state during HFpEF
Both the process of aging and the afore-mentioned comorbidities are thought to initiate a state of chronic systemic low-grade inflammation, considered to be one of the first steps towards preclinical diastolic dysfunction (PDD), and ultimately HFpEF. 9 Systemic inflammation during the early stages of HFpEF is evident from inflammatory biomarker profiles in plasma. 9 Subsequent and concomitant cardiac inflammation involves elevated levels of endothelial adhesion molecules together with increased local production of inflammatory chemo/cytokines, both promoting endothelial dysfunction and immune-cell infiltration. 10 The immune-cells infiltrating the heart contribute to cardiomyocyte hypertrophy 11 and fibrotic remodelling 12 and communicate with the cardiac cell types via paracrine signalling, thereby altering the tissue environment and further contributing to myocardial remodelling and dysfunction.
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The nature of the intracellular communication between immune cells and cardiac resident cells, and the concomitant change in microenvironment, depends on the macrophage polarization state, i.e. whether macrophages are pro-inflammatory (M1) or anti-inflammatory (M2). This state is determined by the local tissue environment, including the presence of specific cytokines like interferon gamma and interleukin-4, and is under the control of various adaptor proteins and transcription factors. 13, 14 By targeting these proteins, some miRNAs (i.e. miR-9, miR-127, miR-155, and miR-125 b) promote M1 polarization, while other miRNAs (miR-124, miR-223, miR-34a, let-7c, miR-132, miR-146a, and miR-125a-5p) induce M2 polarization. 15 Modulation of specific immune cell phenotypes ameliorated cardiac disease outcome in experimental heart failure models such as transverse aortic constriction and angiotensin-II infusion. 11, 16 Complete macrophage depletion might not be the ideal approach since macrophages fulfill both detrimental but also protective functions. Targeting inflammatory microRNAs may enable a more balanced reprogramming, given the fine-tuning nature of microRNAs. Indeed, reprogramming of tumor-associated macrophages is currently considered a promising strategy in cancer therapy, and microRNAs are candidates to achieve this. 15 Further research should aim at understanding the roles of different macrophage phenotypes during cardiac disease in general and HFpEF in particular. 17 
MicroRNAs in cardiac inflammation and macrophage polarization
Although microRNAs are central in controlling immune-cell function and inflammatory activity, 15 the implication of inflammatory microRNAs in HF is so far limited. We showed involvement of the macrophagederived pro-inflammatory microRNA, miR-155, in systolic HF. 11 This 'M1'-associated microRNA mediated pressure overload-induced cardiac inflammation and macrophage-to-cardiomyocyte pro-hypertrophic signalling, indicating that macrophage miR-155 is a crucial factor in driving adverse cardiac remodelling and failure. Whether macrophage miR-155 also plays a role in metabolic syndrome-induced HFpEF is subject of our current investigations. Another well-known inflammatory microRNA, miR-146a, mediates inflammation, and fibrosis in murine diabetic cardiomyopathy. 18 Here, endothelial derived miR-146a was found to regulate diabetes-induced inflammatory cytokine production in the heart through NF-jB. Interestingly, both miR-155 and miR-146a have been associated with obesity, diabetes, and insulin resistance. 15 Whether their central role in inflammation is at the basis of this association remains to be determined. Taken together, though there is some evidence linking specific inflammatory microRNAs with metabolic syndrome and cardiac remodelling, data are still scarce. In addition, there is limited knowledge on specific immune responses in HFpEF. Therefore, future studies exploring the role of microRNAs implicated in macrophages polarization in the context of HFpEF and associated comorbidities are warranted. 
MicroRNAs implicated in
MicroRNAs are implicated in microvascular endothelial dysfunction
The endothelial cell's most enriched microRNA, miR-126, plays a key role in maintaining endothelial homeostasis, and vascular integrity. Puzzlingly, the expression of this microRNA is 50% lower in patients with type 2 diabetes as compared to healthy controls. 27 In mice, loss of miR-126 causes leaky vessels, haemorrhaging, loss of vascular integrity, and defects in endothelial cell proliferation, migration, and angiogenesis. 28 In addition, miR-126 inhibition in endothelial cells was found to increase both VCAM-1 levels and monocyte recruitment. 33 Conceptually the restoration of endothelial miR-126 levels to overcome MVD seems a therapeutically attractive route, although many hurdles to bring this to the clinic have to be taken. Closer to clinical reality may be the use of this microRNA as non-invasive biomarker of MVD, given that circulating miR-126 levels drop dramatically upon diabetes and associated MVD. 27, 29 So far, miR-126 is the only consistent and non-invasive MVD biomarker candidate. Interestingly, transcoronary gradients of miR-133 and -92a were also found to be indicative of microvascular coronary endothelial dysfunction. 30 However, transcoronary blood sampling is clinically unfeasible at large scale. Several studies link inflammatory microRNAs to MVD. Recently, pro-inflammatory cytokines were found to decrease endothelial NO synthase (eNOS) activity and NO production in a miR-138 dependent manner, and the inhibition of miR-138 was suggested to have treatment potential for cardiovascular pathologies linked to endothelial dysfunction. 31 As such, miR-138 inhibition may be an interesting option for NO restoration in the pro-inflammatory endothelial HFpEF environment. The pro-inflammatory miR-155 may also be implicated in MVD. In the brain, inflammatory cytokine-induced endothelial miR-155 targets endothelial cell-cell complex molecules and causes blood brain barrier dysfunction, which is typically regarded as MVD of the central nervous system. 32 Hence, inhibition of miR-155 not only dampens proinflammatory immune-cell activation, but may also positively affect endothelial function. Taken together, specific microRNAs affect endothelial functions (miR-126), NO production (miR-138), and cell-cell contacts (miR-155).
An open question remains whether MVD and its consequences are reversible by treatment, if so, to tackle MVD in the earliest stages could make the difference in the transition of patients from PDD to HFpEF. Once this question is addressed, microRNA-based therapeutics to restore endothelial functions might enter the arena. At this moment, however, microRNA-based therapies have not reached any patient yet, and the road towards this goal is long and bumpy.
MicroRNAs in cardiomyocyte remodelling
The HFpEF heart, an engine out of fuel?
The heart has high energy demands to sustain its contractile function and maintain ionic homeostasis. The cardiomyocyte is extraordinarily flexible to utilize a wide range of substrates taking about 70% of its energy from fat (long chain fatty acids and triacylglycerols) and about 30% from carbohydrates (glucose, glycogen, lactate, pyruvate), ketone bodies and amino acids (leucine, isoleucine, and valine). 33 However, in HFpEF this metabolic flexibility of the cardiomyocyte becomes harmfully limited. Since function and metabolism are inextricably linked in cardiomyocytes, the modulation of cardiac metabolism to improve contractile efficiency of the failing heart has therefore become an appealing clinical goal. 34 Under physiological conditions of normoxia most of the ATP in the heart is derived by fatty acid (FA) b-oxidation (FAO) (i.e. palmitate) coupled to mitochondrial oxidative phosphorylation, as FAO generates the largest amount of ATP (i.e. 1 palmitate molecule generates 105 molecules of ATP). However, it comes at the expense of a greater oxygen requirement than carbohydrate oxidation. 33, 35 Therefore, when oxygen supply becomes limited, e.g. due to MVD and associated capillary rarefaction, the heart prefers the oxidation of carbohydrates (i.e. glucose) as they yield the most ATP per oxygen atom. However, insulin resistance upon obesity and diabetes limits the uptake of glucose by cardiomyocytes, and obesity increases circulating lipid levels, forcing the heart to utilize even more FA in oxygen-deprived conditions. 36 Given that over 80% of HFpEF patients in Western countries are overweight or obese and approximately half of them have diabetes, 37 it is to be anticipated that cardiac energy metabolism in HFpEF gets compromised. In the following paragraphs, we will present current knowledge on the role of microRNAs in both systemic and cardiac energy metabolism.
2.4.1.1 MicroRNAs are implicated in insulin sensitivity during obesity and diabetes. Systemic insulin resistance upon obesity and diabetes affects cardiac metabolism as well. 38 Several microRNAs are associated with impaired insulin sensitivity ( Table 1) . First of all, miR-802 is induced in the liver during obesity and is implicated in the development of obesity-associated impairment of glucose metabolism. 39 The oncomiR, miR-26a, was found to target several key regulators of hepatic metabolism and insulin signalling, and was suggested for further exploration as a potential target for the treatment of T2D. 40 In addition, miR-103/107 levels are elevated in adipose tissue and liver in models of diabetes and obesity 41, 42 and their inhibition in obese mice improved glucose homeostasis and insulin sensitivity. 42 The therapeutic targeting of miR-103/107 seems closest to clinical reality, as the inhibitory agent RG-125 is currently considered for its anti-diabetic actions in NASH patients in a phase I clinical trial (Regulus V R ). This microRNA family has been shown to predominantly target genes implicated in metabolic processes, including FA synthase 43 or regulators of the insulin receptor function, such as Caveolin 1. 42 The clinical application of this promising antidiabetic drug will absolutely constitute a milestone in microRNA-based therapeutics. 44 Interestingly, pharmacological inhibition of miR-33, regulating key enzymes involved in FAO, 45 in a mouse model of diet-induced obesity promoted whole-body oxidative metabolism, however it did not ameliorate metabolic dysfunction. 46 In addition, miR-378 and miR-378*, which were among the first identified 'metabolic' microRNAs, were found to be integral components of a regulatory circuit that functions under conditions of metabolic stress to control systemic energy homeostasis and the overall oxidative capacity of insulin-target tissues. Mice lacking miR-378-3p and miR-378-5p were protected against high-fat diet-induced obesity and show enhanced mitochondrial FA metabolism and elevated oxidative capacity in insulin-target tissues including heart, skeletal muscle, and brown adipose tissue. 47 These authors concluded that these microRNAs, by counterbalancing the metabolic actions of the peroxisome proliferator-activated receptor c coactivator 1b on mitochondrial FA metabolism, provide potential targets for pharmacologic intervention in obesity, and metabolic syndrome. Indeed, the stimulating effect that absence of these microRNAs has on cardiac FAO may render inhibition of miR-378/378* interesting in HFpEF as well. Cardiac MiR-451 is upregulated in a model of type 2 diabetes 48 and controls the energy sensor, 5 0 -AMP-activated protein kinase (AMPK), crucial in the heart with its small energy reserves. Its specific inhibition in the heart may therefore have implications for cardiac metabolism during obesity and diabetes. However, it remains difficult to predict whether stimulation of FAO in a HFpEF heart would tip the cardiac energy balance in the right direction. For this, microRNA inhibitory studies in animal models of HFpEF would be an essential first step.
MicroRNA involvement in cardiomyocyte metabolic
remodelling is largely unexplored. The metabolic syndrome-related changes in metabolic milieu force the cardiomyocyte to undergo metabolic remodelling. MicroRNAs can regulate cardiac metabolic substrate uptake, preference and energy production, including FAO, the tricarboxylic acid (TCA) cycle, and electron transport chain (ETC) activity ( Table 1) .
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Cardiomyocyte substrate uptake changes as a consequence of a change in both supply and demand, and is under control of several microRNAs (Figure 2) . The microRNAs miR-133 and miR-223, which are up-regulated in the failing and insulin resistant heart, have been shown to regulate the insulin-sensitive glucose transporter, GLUT4, in the heart. 50 MiR-1, decreased during cardiac hypertrophy, regulates cardiomyocyte FA uptake via its target the cardiac FA-binding protein FABP3. 51 The regulation of these microRNAs upon cardiac stress may point toward compensatory mechanisms that go against the cardiomyocyte substrate shift upon stress.
FAO is the primary source of ATP in the healthy heart. The entrance of long chain FA into the mitochondria for oxidation depends on mitochondrial membrane transporters including carnitine-acyl carnitine translocase (CACT). MiR-132 and miR-212, up-regulated in obese mice, regulate CACT in liver leading to reduced mitochondria b-oxidation.
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These microRNAs may therefore be subject for investigation in the heart, an organ highly dependent from b-oxidation. MiR-141, upregulated in the diabetic heart, regulates the inner mitochondrial membrane phosphate transporter, Slc25a3, essential for ATP production. 53 Taken together, some microRNAs are implicated in the regulation of cardiomyocyte FAO (Figure 2 ), but their implications for HFpEF-associated cardiomyocyte metabolic remodelling remain to be explored. The mitochondrial TCA cycle and ETC are regulated by microRNAs ( Figure 2) . MiR-146a inhibition during pressure overload in mice improves oxidative cardiomyocyte metabolism via derepression of its target dihydrolipoyl succinyltransferase (DLST), a key component of the TCA cycle. 34 MiR-181a targets another enzyme in the TCA cycle, isocitrate dehydrogenase 1 (IDH1) and thereby inhibits lipid metabolism. 54 Indeed, miR-181a constitutive transgenic mice did not become obese when fed a high fat diet. In the obese and lipid accumulating HFpEF environment, miR-181a administration might be therapeutically considered to attenuate lipid accumulation and prevent lipotoxicity. 54 Its family member, miR-181c, caused increased mitochondrial ROS production in the heart via targeting, and repressing of the mitochondrial encoded cytochrome c oxidase subunit 1 (mt-COX1) involved in the respiratory complex IV. 55 MiR-210 can impact on TCA cycle metabolism by acting negatively on the sulfur cluster assembly enzyme (ISCU1/2), essential for ETC function, and mitochondrial respiration. 56 As the heart highly depends on mitochondrial respiration, it would be of great interest to investigate the roles of these microRNAs in cardiomyocytes during the metabolically challenging conditions leading to HFpEF. In summary, microRNAs regulate energy metabolism at various levels. However, the role of microRNAs in the response of the cardiomyocyte to the systemic metabolic challenges imposed by the metabolic syndrome is largely unexplored. The identified broad-scale effects of microRNAs on metabolic processes, imply that more research efforts should be directed towards the understanding of microRNA-mediated cardiomyocyte metabolic remodelling. Unfortunately, the intricate nature of metabolic processes at the systemic level, as well as their close association to cancer processes, renders metabolic microRNA targeting challenging as therapeutic approach.
Cardiomyocyte structural remodelling
Cardiomyocyte hypertrophy, present at varying degrees, is one of the most common structural abnormalities associated with HFpEF. Diminished cGMP-PKG signalling, the result of reduced NO bioavailability, has been proposed to be central in the cascade of cardiomyocyte events feeding into cardiac diastolic dysfunction, as it causes hypertrophy as well as hypo-phosphorylation of the elastic sarcomeric protein, titin, the responsible for cardiomyocyte stiffness. 5 Titin is a giant elastic protein expressed in cardiomyocytes in two main isoforms, N2B (stiffer spring), and N2BA (more compliant spring). In addition to alterations in the phosphorylation state of titin and oxidative stress-induced formation of disulfide bridges within the titin molecule, 1 titin isoform switching to a more abundant N2BA may increase myocardial passive stiffness. 57, 58 In addition, other factors contribute to the impairment of cardiomyocyte relaxation function in HFpEF. Normal heart pump function is driven by the intricately regulated cyclic release and reuptake of calcium to and from the cytoplasm of cardiomyocytes in the process of excitationcontraction (E-C) coupling. During normal E-C coupling, depolarization of the cardiomyocyte sarcolemma by an action potential induces a small influx of calcium through the L-type calcium channels (LTCC), triggering a much larger release of calcium from the sarcoplasmic reticulum by stimulating the ryanodine receptor (RyR) calcium release channel. Calcium then allows for actin-myosin myofilament cross-bridging and force production. Finally, calcium is removed from the cytoplasm, primarily via the sarcoplasmic reticulum calcium ATPase, SERCA2a, and the sarcolemmal sodium-calcium exchanger (NCX), leading to relaxation. Here, NO-dependent cGMP plays a role in reducing myofilament calcium-sensitivity and facilitating cross-bridge detachment for relaxation, a process that is disturbed in NO-deprived HFpEF hearts. The NOdownstream mediator cGMP is lower in the HFpEF heart and this leads to compromised phosphorylation of sarcomeric proteins involved in calcium handling, including SERCA2a. As a consequence sarcoplasmic reticulum calcium-reuptake is delayed and this results in delayed early relaxation of the cardiomyocyte. Moreover, since the cardiomyocyte relaxation is an energy-consuming process, impaired relaxation can also result from a myocardial energy deficit. 60 MiR-133 and miR-1, highly abundant in cardiomyocytes, were among the first miRNAs to be associated with cardiac pathological growth. 61, 62 Very recently, miR-208 b was linked to titin truncation-induced dilated cardiomyopathy (DCM). MiR-208 b is upregulated in patients with severe DCM and its inhibition prevented DCM onset in a mouse model harbouring a titin knock-in truncation. 63 The exact molecular link between titin and miR-208 b remains unknown, Figure 2 Cardiomyocyte energy metabolism is regulated by microRNAs. Glucose enters the cell via its transporter GLUT1/4 and it is transformed into pyruvate by glycolysis, which enters the mitochondria and is converted to acetyl-CoA by pyruvate dehydrogenase (PDH), a multi-enzyme complex of several subunits. Inside the mitochondrial matrix, acetyl-CoA enters the TCA cycle. This results in production of redox-equivalents, which enter the electron transport chain (ETC), and drive the electrochemical proton gradient. Fatty acids enter the cell membrane via fatty acid transporters (FAT/CD36) at the cell membrane and Carnitine palmitoyltransferase (CPT) at the mitochondrial membrane before being used by b-oxidation and ETC to produce ATP.
Pathophysiological understanding of HFpEF: microRNAs as part of the puzzle but these data identify miR-208 b as an interesting candidate for further investigation in titin-dysregulation during HFpEF. Diminished cGMP-PKG activity compromises phosphorylation of sarcomeric proteins involved in calcium handling, including calmodulin, a critical mediator of calcium signals. The muscle-specific microRNA, miR-1, post-transcriptionally regulates calmodulin during heart failure. 64 MiR-1 also negatively regulates the expression of Mef2a and Gata4, key transcription factors that mediate calcium-dependent changes in gene expression. 64 In addition, miR-22, upregulated in cardiomyocytes after phenylephrine or angiotensin II stimulation, regulates SERCA2a transporting activity and thereby regulates the sarcoplasmic reticulum calcium reuptake. 65 Cardiomyocytes from miR-22 KO animals did not adapt well to haemodynamic stress by b-adrenergic stimulation or pressure overload, because of reduced SERCA2a levels following the de-repression of the direct miR-22 target, the SERCA2a the transcriptional/translational repressor, purine-rich element binding protein B. Vice versa, cardiac miR-25, upregulated during heart failure, and inhibiting SERCA2a, was shown to potently delay calcium uptake kinetics in cardiomyocytes and its in vivo inhibition led to improved cardiac function and survival in a mouse model of aortic constriction-induced heart failure. 66 MiR-181 b, significantly increased in the peripheral blood of patients with cardiac hypertrophy, has been shown to regulate the expression of PKG-1. 67 In phenylephrine-treated cardiomyocytes, an in vitro model of hypertrophy, the inhibition of miR-181 b led to restored expression of PKG-1, and alleviated cardiomyocyte hypertrophy. MiR-181 b may therefore be a novel target for the regulation of the cGMP-PKG signalling pathway.
MicroRNAs in cardiac fibrosis
Fibrotic remodelling and the HFpEF heart
Myocardial fibrosis is entangled in the pathogenesis of HFpEF as well as an important hallmark of aging. 68 Increased collagen volume fraction, higher expression of collagen type I, and increased collagen cross-linking are associated with myocardial stiffness and as a result with impaired diastolic function. 69 Collagen deposition in the HFpEF heart may result from different causalities: (1) transforming growth factor b (TGFb), released by infiltrating monocytes/macrophages, favours the differentiation of fibroblasts into collagen-producing myofibroblasts 70 ; (2) microvascular inflammation induces the proliferation of fibroblasts due to reduced NO bioavailability 71 ; and (3) pressure overload-induced growth promoting-hormones such as endothelin-1, angiotensin II, and aldosterone have a pro-fibrotic action. 72 The role of microRNAs in cardiac fibrosis has been extensively reviewed recently. 73 Here, the most studied cardiac fibro-miRs are discussed briefly.
MicroRNAs in cardiac fibrosis
TGFb/Smad signalling induces the abundant cardiac microRNA, miR-21, which is particularly enriched in fibroblasts of the failing heart. 74 This stress-responsive pro-fibrotic microRNA is central to cardiac fibroblast function, in which it regulates ERK-MAP kinase signalling, essential for fibroblast survival, and activation. In addition, miR-21 positively regulates TGFb signalling through its target Smad7, an inhibitor of Smad2/3. In vivo inhibition of miR-21 prevents the development of pressure overloadinduced cardiac interstitial fibrosis and cardiac dysfunction. 75 Promisingly, its inhibitor, RG-012, is currently under clinical development for kidney fibrosis in Alport syndrome (Regulus V R ). MiR-21 inhibits apoptosis of cardiac fibroblasts and was implicated in cardiac fibrosis in a rat model of HFpEF. 76 Downstream in the pro-fibrotic TGFb signalling cascade is the connective tissue growth factor (CTGF), which is under the control of multiple microRNAs, including miR-133, miR-30, and the miR-1792 family members, miR-18a and -19a. 61 Interestingly, this miR-1792 cluster, encoding six microRNAs (miR-17, miR-18a, miR-19a, miR-19 b, miR-20a, and miR-92a-1), has a central role in the regulation of matrix genes and in cellular aging. 77 This cluster is part of the senescence signature of the aged cardiomyocyte and its expression decreased in a murine model of age-related heart failure. 78 In particular, miR-18a and19a were shown to target thrombospondin-1 and to regulate collagen levels. Members of the miR-29 family are also implicated in the development of cardiac fibrosis. In the heart, inhibition of microRNA-29 in vivo resulted in enhanced collagen deposition, whereas introduction of microRNA-29 mimics after cardiac damage reduced collagen content. Downstream targets of miR-29 include the extracellular matrix-related genes such as elastin, collagenase type 1 alpha 1-3 and fibrillin 1. 79 The most abundant microRNA in the heart, miR-22, 80 is strongly associated with pro-fibrotic signalling, cardiac hypertrophy and aging. 81 In vitro miR-22 overexpression in neonatal rat cardiac fibroblasts led to premature senescence via its target mimecan/osteoglycin (OGN), which we recently showed to be essential to maintain integrity of the aged heart. 82 High levels of miR-22 during aging may therefore be quite undesirable. Whereas all these microRNAs seem to offer opportunities for targeting and improving cardiac fibrotic remodelling upon failure or aging, the first proof of principle will probably come from miR-21 inhibition, with the presumption that the entry of RG-012 into the clinic proceeds as expected without adverse events.
3. Can microRNAs help direct future diagnosis and therapy for HFpEF? 3.1 The use of the plasma signature of microRNAs as biomarkers for disease Extracellular microRNAs are remarkably stable as a result of their association with RNA-binding proteins and lipoproteins, or their shedding in membrane-derived vesicles (MVs). The cell-cell communication hypothesis states that extracellular microRNAs act as paracrine signalling molecules. 83 However, the biological role of extracellular microRNAs is still under debate. The existence of a mechanism controlling the extracellular secretion of microRNAs has so far not been uncovered. The presence of miR-126 in endothelial microparticles (EMPs) regulates VEGF responsiveness and confers vascular protection in a paracrine manner. 84 During diabetes, endothelial cell expression of miR-126 is lost, as is its presence in EMPs, 27 possibly explaining vascular damage in diabetics.
This important mechanistic study associates an extracellular microRNA with cell-cell signalling. Independent of their passive or regulated release, extracellular microRNAs can serve as biomarkers. For example, injured cardiac cells release the cardiomyocyte-specific miR-208 with a similar time course as cardiac troponin I--the classic protein biomarker of myocardial injury. 85 The presence of cardiomyocyte-specific microRNAs in the circulation seems to correlate to the extent of acute cardiac damage, 86 and hence cardiomyocyte-specific microRNAs may be unsuitable for the diagnosis of a chronic disease like HFpEF. Consistently behaving alternative microRNAs for the identification of cardiac disease types remain to be identified. 
MicroRNAs as novel biomarkers for HFpEF
The usefulness of current clinical biomarkers to diagnose HFpEF is limited. The most important HF biomarker, NT-proBNP, is moderately increased and has poor predictive value in HFpEF. 87 Recently, a unique metabolic fingerprint for HFpEF patients was proposed by the combined use of magnetic resonance spectroscopy and metabolite measurements in serum. 88 Other biomarkers that can add additional prognostic value over NT-proBNP and that emerge as predictive for hospitalization and death in HFpEF and preclinical diastolic dysfunction are galectin-3 and suppression of tumorigenicity 2 (ST2). 89 Besides, a number of other molecules are being studied as biomarkers for HFpEF, and more specifically for cardiac fibrosis or inflammation, including tissue inhibitor of metalloproteinases, aminoterminal propeptide of type III procollagen, homocysteine, resistin, pentraxin-3, tumor necrosis factor alpha, interleukin (IL)-6, and IL-10. 89 Consensus on microRNA candidates for HFpEF biomarkers is currently lacking. Researchers so far seem to focus their search for microRNA signatures to distinguish between HFpEF and HFrEF. Wong et al. 87 identified a subset of circulating microRNAs that could differentiate HFrEF from HFpEF independent from comorbidities like diabetes and hypertension ( Table 2) . However, Watson et al. 90 and Nair et al. 91 found completely different profiles of circulating microRNAs that distinguished HFrEF from HFpEF patients ( Table 2) . Much more interesting than distinguishing HFpEF from HFrEF patients, would be the discovery of biomarkers indicating PDD, because this would allow for the identification of high-risk patients, the implementation of preventive therapies, and disease monitoring. In diabetes and obesity, circulating microRNAs seem to correlate well with insulin resistance, 92 and specific circulating microRNAs have been found to reflect response to therapy: increased plasma miR-140-5p in obese or diabetic subjects decreased again after treatment with metformin or bariatric surgery, and increased serum miR-192 and miR-193 b in pre-diabetic subjects returned to baseline after therapeutic intervention or chronic exercise. 93 In addition, serum biomarkers of cardiac fibrosis reflect severity of heart failure, 94 and the identification of pathophysiological processes like fibrosis may be meaningful in stratifying HF patients. The biggest challenge in comparing human studies is the clear lack of standardized protocols for the detection and absolute quantification of microRNAs, leading to the present intra-and inter-laboratory variations. 95 MicroRNAs may be highly suitable sentinels of specific pathophysiological processes underlying HFpEF, including inflammation, endothelial dysfunction, cardiomyocyte remodelling, and cardiac fibrosis ( Figure 3) . Ultimately, circulating microRNAs may allow for HFpEF patient stratification, prognostic indication, and monitoring of response to therapy.
3.1.1.1 MicroRNA-based therapeutics: opportunities and challenges. The promising results of the miR-122 targeting drug, Miravisen, to treat chronic hepatitis C virus patients, 96 and the initiation of clinical trial studies using microRNA-based strategies to target cardiac fibrosis (anti-miR-21) and hepatic glucose and lipid metabolism (anti-miR-103/ 107), are encouraging for the development of microRNA-based therapeutics for diseases like HFpEF. One major challenge for conducting mechanistic studies on HFpEF for the unravelling of HFpEF pathophysiology and validation of therapeutic targets for HFpEF, is the limited availability of in vitro and in vivo models. A number of animal models have been developed that recapitulate some of the characteristics of HFpEF, however, they yet fall short of capturing the complexity of the human disease. For example, the ZSF1 rat is considered a promising model that combines obesity, diabetes, and hypertension. 97 However, a major current drawback of this model is that so far only male rats have been characterized. Given that HFpEF is considered a female disease, taking into account female postmenopausal or ovariectomized rats should be considered. Another example is the Dahl/salt-sensitive/obese rat, which develops LV diastolic dysfunction, hypertrophy and fibrosis, associated with increased cardiac oxidative stress and inflammation. Examining the efficacy of targeting specific candidate microRNAs to overcome inflammation, MVD, cardiomyocyte exhaustion and stiffness, and fibrosis in these rats will probably be the first step towards microRNA-based HFpEF therapeutics. The currently available range of microRNA inhibitors or mimicking agents has been extensively reviewed elsewhere. 98 
Conclusions
Significant progress has been made in understanding the pathophysiology of HFpEF and identifying the importance of comorbidities. However, there is still lack of effective treatment. Inflammation, MVD, metabolic impairment, cardiomyocyte stiffness, and fibrosis are underlying pathophysiological mechanisms that could be targeted. Understanding pathophysiological mechanisms that lead to HFpEF could help shifting the therapeutic strategy from 'one fits all' to an approach based on patient phenotype characterization and stratification. MicroRNAs, with roles in specific HFpEF-underlying pathophysiological processes, have biomarker potential and may be usable as patient 'pheno-groupers'. In addition, the therapeutic potential of microRNAs is interesting though preliminary, and the field is expectantly awaiting the results of clinical trials using microRNA-targeting drugs. Therefore, microRNA-based coupling of diagnosis and therapy would be a dream scenario to achieve real personalized medicine, but is at this moment not within reach. Here, we presented current state-of-the-art and suggest microRNA candidates that are emerging as potential HFpEF stratifiers and/or therapeutic targets. It is clear that further experimental and clinical studies are needed to select candidate microRNAs to do this job.
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